Zoetis Inc. (ZTS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Zoetis Inc. (ZTS) Healthcare & Pipeline Overview

Zoetis Inc. (ZTS) is a leading animal health company providing medicines, vaccines, and diagnostics for livestock and companion animals. With a strong global presence and a focus on innovation, Zoetis serves veterinarians, livestock producers, and retail outlets, contributing to animal health and food safety worldwide. The company boasts a 70.5% gross margin.

What Is the Investment Thesis for ZTS?

Zoetis Inc. presents a notable research candidate due to its leading position in the growing animal health market. The company's diverse portfolio of products and services, catering to both livestock and companion animals, provides a stable revenue base. With a market capitalization of $30.6B and a healthy profit margin of 28.2%, Zoetis demonstrates financial strength. Key growth catalysts include the increasing demand for animal protein, the rising pet ownership globally, and the expansion of its diagnostic offerings. The company's commitment to innovation and strategic acquisitions further strengthens its competitive advantage. However, investors should be aware of potential risks, such as regulatory changes and competition from other animal health companies. The company's beta of 0.97 indicates lower volatility than the overall market. The dividend yield of 1.83% provides an additional return for investors.

Based on FMP financials and quantitative analysis

ZTS Key Highlights

Market capitalization of $30.6B reflects Zoetis's strong market position in the animal health industry.

• P/E ratio of 11.64 suggests a reasonable valuation compared to its earnings.
• Profit margin of 28.2% indicates efficient operations and strong profitability.
• Gross margin of 70.5% demonstrates the company's ability to maintain high pricing power and manage costs effectively.
• Dividend yield of 1.83% provides a steady income stream for investors.

Who Are ZTS's Competitors?

ZTS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ZTS's Key Strengths?

Leading market position in the animal health industry.

• Diverse product portfolio catering to both livestock and companion animals.
• Global reach and distribution network.
• Strong financial performance and profitability.

What Are ZTS's Weaknesses?

Dependence on regulatory approvals for new products.

• Exposure to currency fluctuations.
• Potential for product liability claims.
• Vulnerability to economic downturns affecting animal health spending.

What Could Drive ZTS Stock Higher?

Potential regulatory approvals for new animal health products in key markets.

• Increasing demand for animal protein and rising pet ownership driving market growth.
• Expansion of Zoetis's diagnostic offerings and services.
• Strategic acquisitions and partnerships to expand product portfolio and geographic reach.

What Are the Key Risks for ZTS?

Changes in government regulations affecting animal health products.

• Outbreaks of animal diseases impacting demand for vaccines and therapeutics.
• Competition from other animal health companies.
• Economic downturns affecting animal health spending.
• Product liability claims and recalls.

What Are the Growth Opportunities for ZTS?

• Expansion of Companion Animal Products: The increasing pet ownership globally, particularly in emerging markets, presents a significant growth opportunity for Zoetis. The company can capitalize on this trend by expanding its portfolio of companion animal products, including vaccines, parasiticides, and other pharmaceutical products. The global companion animal health market is estimated to reach $30 billion by 2028, growing at a CAGR of 6.5%. Zoetis can leverage its strong brand reputation and distribution network to capture a larger share of this market.
• Growth in Emerging Markets: Emerging markets, such as China, India, and Brazil, offer significant growth potential for Zoetis. The increasing demand for animal protein in these markets is driving the growth of the livestock industry, creating a need for animal health products. Zoetis can expand its presence in these markets through strategic partnerships, acquisitions, and the introduction of new products tailored to local needs. The animal health market in emerging markets is expected to grow at a faster rate than in developed markets.
• Development of New Vaccines and Therapeutics: Zoetis's commitment to research and development allows it to develop new and improved vaccines and therapeutics for both livestock and companion animals. The company can focus on developing products that address unmet needs, such as vaccines for emerging diseases and therapeutics for chronic conditions. The global animal vaccine market is estimated to reach $10 billion by 2027, growing at a CAGR of 7.2%.
• Expansion of Diagnostic Offerings: The increasing focus on preventive care and early disease detection is driving the growth of the animal diagnostics market. Zoetis can expand its diagnostic offerings by developing new and improved diagnostic tests and services for both livestock and companion animals. The global animal diagnostics market is estimated to reach $5 billion by 2026, growing at a CAGR of 8.5%. Zoetis can leverage its expertise in animal health to develop innovative diagnostic solutions that meet the needs of veterinarians and livestock producers.
• Strategic Acquisitions and Partnerships: Zoetis can continue to grow through strategic acquisitions and partnerships. The company can acquire companies with complementary products or technologies, expanding its product portfolio and geographic reach. It can also partner with other companies to develop and commercialize new products. Strategic acquisitions and partnerships can help Zoetis accelerate its growth and maintain its competitive advantage.

What Are ZTS's Competitive Advantages?

• Strong brand reputation and customer loyalty.
• Diverse product portfolio catering to both livestock and companion animals.
• Global reach and distribution network.
• Commitment to research and development and innovation.
• Regulatory expertise and compliance.

What Does ZTS Do?

Zoetis Inc., founded in 1952 and headquartered in Parsippany, New Jersey, is a global leader in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products. Originally a part of Pfizer's animal health division, Zoetis became an independent publicly traded company in 2013. The company's diverse portfolio caters to both livestock and companion animals, addressing a wide range of health needs. For livestock, Zoetis offers products for cattle, swine, poultry, fish, and sheep, focusing on disease prevention and treatment to improve productivity and food safety. For companion animals, including dogs, cats, and horses, the company provides solutions for preventing and treating diseases, managing pain, and improving overall well-being. Zoetis's product offerings include vaccines, anti-infectives, parasiticides, and other pharmaceutical products, such as pain and sedation medications, dermatology products, and medicated feed additives. The company also provides diagnostic products and services, including portable blood and urine analysis testing, rapid immunoassay tests, and reference laboratory services. Zoetis markets its products globally through a network of sales representatives, technical specialists, veterinary operations specialists, and third-party distributors, serving veterinarians, livestock producers, and retail outlets. With a strong focus on innovation and a commitment to animal health, Zoetis continues to expand its product portfolio and geographic reach, solidifying its position as a leading player in the animal health industry.

What Products and Services Does ZTS Offer?

• Discovers and develops animal health medicines and vaccines.
• Manufactures and commercializes animal health products globally.
• Offers products for livestock, including cattle, swine, poultry, fish, and sheep.
• Provides solutions for companion animals, such as dogs, cats, and horses.
• Offers vaccines, anti-infectives, and parasiticides.
• Provides diagnostic products and services, including blood and urine analysis testing.
• Markets products to veterinarians, livestock producers, and retail outlets.

How Does ZTS Make Money?

• Develops and manufactures animal health products.
• Sells products through sales representatives, distributors, and retail outlets.
• Generates revenue from the sale of medicines, vaccines, and diagnostic products.
• Invests in research and development to create new products and improve existing ones.

What Industry Does ZTS Operate In?

Zoetis operates in the global animal health market, which is experiencing steady growth driven by factors such as the increasing demand for animal protein, the rising pet ownership, and the growing awareness of animal health and welfare. The market is competitive, with several major players, including ELV: Elevance Health Inc., CI: Cigna Corporation, and REGN: Regeneron Pharmaceuticals, Inc. Zoetis differentiates itself through its diverse product portfolio, global reach, and strong focus on innovation. The company's commitment to research and development allows it to introduce new and improved products, maintaining its competitive edge. The animal health market is expected to continue growing in the coming years, driven by the factors mentioned above, as well as the increasing prevalence of animal diseases and the growing demand for preventive care.

Who Are ZTS's Key Customers?

• Veterinarians who use Zoetis products to treat and prevent diseases in animals.
• Livestock producers who use Zoetis products to improve the health and productivity of their animals.
• Pet owners who purchase Zoetis products to care for their companion animals.
• Retail outlets that sell Zoetis products to consumers.

Over the past six months, Zoetis Inc. insiders filed 45 SEC Form 4 transactions — 9 sales and 36 purchases. On net that is roughly 103K shares acquired (about $816K) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: Zoetis Inc.

Revenue for Zoetis Inc. came in at $2.47B during Q2 FY2026, a 9.1% improvement versus the preceding quarter. The company recorded net income of $691.0M, with diluted EPS of $1.65. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, ZTS averaged $1.52 in diluted EPS.

ZTS Valuation & Market Position

With a $30.6B market cap, Zoetis Inc. sits in the large-cap segment of the market. Analyst price targets span from $80.00 to $95.00, with a consensus of $87.33. At the current price of $72.89, that implies approximately 20% upside potential. Relative to its peer group, ZTS's quantitative score of 85/100 is above the peer average of 74/100.

Return on equity for Zoetis Inc. stands at 69.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 17.4%, showing how much profit it generates from its asset base. ZTS trades at a trailing price-to-earnings ratio of 11.64, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 7.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.08 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 8.6%, the inverse of the P/E and a quick read on earnings relative to price.

Zoetis Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 4.65 places it in the safe zone, indicating low near-term bankruptcy risk.

Zoetis Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 3.9% above estimates on average.

Company Profile

Zoetis Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Parsippany, US. The company is led by CEO Kristin C. Peck. ZTS has traded publicly since 2013.

ZTS Financials

ZTS Latest News

ZTS Analyst Consensus

ZTS MoonshotScore

Latest Zoetis Inc. Analysis

Zoetis Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources